Auxetic stents for the management of venous stenosis

Auxetic stents address the issue of venous stenosis by expanding longitudinally with radial expansion, enhancing luminal gain and venous flow while minimizing adjacent vein narrowing, providing a more effective treatment for venous stenosis.

JP7577662B2Active Publication Date: 2024-11-05OREGON HEALTH & SCI UNIV
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2021538233
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-07-22
Filing Date
2020-01-10
Publication Date
2024-11-05
Estimated Expiration
2040-01-10

AI Technical Summary

Technical Problem

Current stents designed for arterial use fail to effectively manage venous stenosis due to the anisotropic elasticity of veins, leading to incomplete expansion and subsequent narrowing of adjacent vein segments, which can result in occlusion and inadequate treatment of venous outflow obstruction.

Method used

The use of auxetic stents with negative Poisson's ratio, which expand longitudinally when radially expanded, to actively control both radial and longitudinal biomechanical forces, preventing transmitted forces to adjacent vein segments and improving luminal gain.

Benefits of technology

Auxetic stents provide enhanced luminal gain and improved venous flow by expanding axially while maintaining radial diameter, reducing the risk of adjacent vein narrowing and occlusion, thus offering a more effective treatment for venous stenosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007577662000001
    Figure 0007577662000001
  • Figure 0007577662000002
    Figure 0007577662000002
  • Figure 0007577662000003
    Figure 0007577662000003
Patent Text Reader

Abstract

Disclosed is a stent that can be used to treat venous stenosis. In embodiments, the stent is configured to be auxetic, expanding axially as it expands radially to prevent tension on vessel sections adjacent to the stented section of the vessel, thereby preventing stenosis in the adjacent sections and improving luminal gain. The stent can include one or more axially deformable cross members to allow the axial length of the stent to be adjusted while maintaining a constant diameter and further to allow the stent to bend to conform to the curvature of the vessel.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001]

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 791,091, filed January 11, 2019, and U.S. Provisional Patent Application No. 62 / 876,994, filed July 22, 2019, both of which are entitled "AUXETIC STENTS FOR MANAGING VENOUS STENOSIS," the entire disclosures of both applications are incorporated herein by reference. [Technical field]

[0002]

[0002] The present disclosure relates to stents that can be used in medical environments, and in particular to auxetic stents that can be used to manage venous stenosis.

[0003] background

[0004]

[0003] According to statistics from the Centers for Disease Control and Prevention, the annual incidence of venous thromboembolism is estimated at 900,000 cases per year (1-2 cases per 1,000 people). Post-thrombotic syndrome (PTS) is a long-term complication associated with deep vein thrombosis (DTV) that can cause long-term symptoms such as pain, swelling, and heaviness. Given the relatively high prevalence and associated symptoms, previous studies have suggested that the socioeconomic impact associated with chronic venous disease in the United States is at least $200 million. [Brief description of the drawings]

[0005] [Figure 1A] FIG. 1A is a side view of an example of an auxetic stent for treating venous stenosis in a re-entrant orthogonal configuration, according to various embodiments. [Figure 1B] FIG. 1B is an axial view of the example auxetic stent of FIG. 1A, according to various embodiments. [Figure 1C] FIG. 1C is a diagram of a cell array including the example auxetic stent of FIGS. 1A and 1B, according to various embodiments. [Diagram 2] FIG. 2 is a side view of an example auxetic stent expanded radially to 14 mm, according to various embodiments. [Diagram 3] FIG. 3 is a side view of the example auxetic stent of FIG. 2 radially relaxed to 12 mm, according to various embodiments. [Figure 4] FIG. 4 is a side view of the example auxetic stent of FIG. 2 radially compressed to 2.5 mm, according to various embodiments. [Diagram 5] FIG. 5 shows an example cell that can include an auxetic stent in a compressed configuration down to 2.5 mm, according to various embodiments. [Figure 6] FIG. 6 shows the example cell of FIG. 5 enlarged to 14 mm, according to various embodiments. [Figure 7] FIG. 7 shows the example cell of FIG. 6 released and axially compressed to 12 mm, according to various embodiments. [Figure 8] FIG. 8 illustrates the example cell of FIG. 7 axially stretched, according to various embodiments. [Figure 9] FIG. 9 shows another example auxetic stent comprised of cells having a rotachiral rhomboidal configuration, according to another embodiment. [Figure 10] FIG. 10 shows another example auxetic stent comprised of cells having a rotachiral orthogonal configuration, according to another embodiment. [Figure 11] FIG. 11 shows a comparison of the configuration of a standard (non-auxetic) stent in a deployed vein with the configuration of an auxetic stent deployed in a vein, according to various embodiments. [Figure 12] FIG. 12 is a flow chart of an example method of using an auxetic stent in treating a venous stenosis, according to various embodiments. [Figure 13] FIG. 13 illustrates end and central segments of an auxetic stent including axial protrusion engagement features in a compressed configuration, according to various embodiments. [Figure 14]FIG. 14 illustrates in an enlarged configuration the ends and central segments of the auxetic stent of FIG. 13 including axial protrusion engagement features, according to various embodiments. [Figure 15] FIG. 15 shows an example of an auxetic stent manufactured in a similar configuration to the stent shown in FIGS. 13 and 14, according to various embodiments. [Figure 16] FIG. 16 shows two example auxetic stents having a configuration similar to the stent shown in FIG. 15, where one stent is expanded and the other is compressed and loaded onto a catheter, according to various embodiments. [Figure 17] FIG. 17 is a venogram of a normal iliac vein prior to deployment of a stent similar to that shown in FIG. [Figure 18] FIG. 18 is a venogram of the iliac vein shown in FIG. 17 after deployment of a stent similar to that shown in FIG. [Figure 19A] FIG. 19A is a venogram of a vein with an auxetic stent in place, similar to the stent shown in FIG. 15, in hip extension. [Figure 19B] FIG. 19B is a venogram of a vein with an auxetic stent in place, similar to the stent shown in FIG. 15, in a flexed position. [Figure 20] FIG. 20 shows the inferior vena cava with an auxetic stent in place, similar to the stent depicted in FIG. [Figure 21] FIG. 21 shows a comparison of the compatibility of non-auxetic materials (a) and auxetic materials (b) according to various embodiments. [Figure 22] FIG. 22 is a venogram of an auxetic stent showing its conformity to the venous anatomy. [Diagram 23] FIG. 23 shows the cell auxetic stent portions of Examples 10 and 12 in an unstrained starting position, according to various embodiments. [Figure 24] FIG. 24 illustrates the stent portion of the example of FIG. 23 in a crimped position, according to various embodiments. [Diagram 25]FIG. 25 shows the stent portion of the example of FIG. 23 deployed to 12 mm, according to various embodiments. [Figure 26] FIG. 26 illustrates the example stent portion of FIG. 23 in an axially stretched configuration while constrained radially to 12 mm, according to various embodiments. [Figure 27] FIG. 27 illustrates the stent portion of the example of FIG. 23 returned to a neutral axial position, according to various embodiments. [Figure 28] FIG. 28 illustrates the example stent portion of FIG. 23 in an axially compressed configuration while being constrained radially to 12 mm, according to various embodiments. [Figure 29] FIG. 29 shows cell lengths for each of the example stent portions of FIG. 23 when each example stent is manipulated through the configurations shown in FIGS. 24-28, according to various embodiments. [Diagram 30] FIG. 30 shows cell length as a function of stent diameter for the example stent portion of FIG. 23 when each example stent is manipulated through the configurations shown in FIGS. 24-28, according to various embodiments. [Diagram 31] FIG. 31 shows the total axial force as a function of cell length for the example stent portion of FIG. 23 as each example stent is manipulated through the configurations shown in FIGS. 24-28, according to various embodiments. [Diagram 32] FIG. 32 shows total radial force as a function of stent diameter for the example stent portion of FIG. 23 as each example stent is manipulated through the configurations shown in FIGS. 24-28, according to various embodiments. [Diagram 33] FIG. 33 shows the normalized total outward radial force over time of the stent portion of the example of FIG. 23 as each example stent is manipulated through the configurations shown in FIGS. 24-28, according to various embodiments. [Diagram 34] FIG. 34 shows a finite element analysis model illustrating the stenosis of an unstented vein segment adjacent to a stented vein segment. [Diagram 35]FIG. 35 shows three venograms: on the left a venogram of a normal vein, in the middle a venogram of a stenosed vein using endovenous radiofrequency ablation, and on the right a venogram after deployment of an auxetic stent. [Diagram 36] FIG. 36 shows graphs from a finite element analysis of a vascular model, demonstrating a higher relative adjacent vessel diameter reduction during angioplasty in a vein compared to an artery (left graph), and a higher vessel wall longitudinal displacement / strain during angioplasty in a vein compared to an artery (right graph). [Figure 37] Figure 37 shows a comparison of vein anatomy when an auxetic stent is placed in the left vein and an open cell stent is placed on the right, narrowing the diameter of the vein adjacent to the open cell stent.

[0006] Detailed Description

[0007]

[0043] In the following detailed description, reference is made to the accompanying drawings, which form a part hereof, and which show by way of example embodiments that may be practiced. It is to be understood that other embodiments may be utilized and structural or logical changes may be made without departing from the scope. Therefore, the following detailed description is not to be taken in a limiting sense, and the scope of the embodiments is defined by the appended claims and their equivalents.

[0008]

[0044] Various operations may be described sequentially or as multiple discrete operations to aid in understanding the embodiments, however, the order of description should not be construed to imply that these operations are order dependent.

[0009]

[0045] The description may use perspective-based descriptions such as top / bottom, back / front, top / bottom, etc. Such descriptions are used merely for ease of discussion and are not intended to limit the application of the disclosed embodiments.

[0010]

[0046] The terms "coupled" and "connected," along with their derivatives, may be used. It should be understood that these terms are not intended as synonyms for each other. Rather, in certain embodiments, "connected" may be used to indicate that two or more elements are in direct physical contact with each other. "Coupled" means that two or more elements are in direct physical contact. However, "coupled" can also mean that two or more elements are not in direct contact with each other, but still cooperate or interact with each other.

[0011]

[0047] For purposes of illustration, a phrase in the form "A / B" or "A and / or B" means (A), (B) or (A and B). For purposes of illustration, a phrase in the form "at least one of A, B and C" means (A), (B), (C), (A and B), (A and C), (B and C) or (A, B and C). For purposes of illustration, a phrase in the form "(A)B" means (B) or (AB), i.e., A is an optional element.

[0012]

[0048] The terms "embodiment" or "embodiments" may be used herein, and each of these terms may refer to one or more of the same or different embodiments. Furthermore, terms such as "comprising," "including," and "having," when used with respect to an embodiment, are synonymous.

[0013]

[0049] The two main contributing factors in the pathophysiology of post-thrombotic syndrome (PTS) are venous outflow obstruction due to stenosis associated with chronic venous fibrosis and venous valve insufficiency. In patients with venous outflow obstruction due to chronic fibrosis, treatment with venous stents has been shown to improve blood flow with short-term clinical relief. However, approximately 25% of stents placed for thrombosis become occluded over a 3-5 year period, and many more stents become occluded in the chronic total occlusion recanalization patient population. Unfortunately, the stents used in these reports were originally designed for use outside the artery or vasculature. The pathophysiology of PTS is not fully understood, but previous studies have suggested that one of the main contributing factors is venous outflow obstruction due to stenosis associated with chronic venous fibrosis (venous stenosis).

[0014]

[0050] Based on a retrospective analysis of venograms before and after iliac vein stenting, significant stenosis of the external iliac vein occurred after placement of an adjacent common iliac vein stent. Furthermore, the degree of stenosis is associated with a relative increase in common iliac vein diameter. These findings indicate that biomechanical forces are transmitted to adjacent venous segments after stent placement, and the degree of transmitted force is related to the radial force (the force exerted by the stent as it expands) in the treated segment. The anisotropic elasticity of veins has been previously described, quantified, and modeled and is a key property for understanding this observation.

[0015]

[0051] Anisotropic elasticity refers to the non-uniform mechanical response of veins that depends on the direction in which stress is applied. Specifically, previous in vitro studies have shown that veins are less extensible in the longitudinal direction relative to the circumferential direction when compared to arteries. This is relevant to the biomechanics of veins because the application of radial forces results in longitudinal forces due to the Poisson effect, which is an inherent property of the materials that comprise veins. If the longitudinal stiffness of a vein under high pressure is relatively high, the resultant longitudinal force due to the Poisson effect will result in contraction, e.g., shortening in length, in the portion of the vein adjacent to the stent location during the application of radial forces associated with stent placement. We have demonstrated this Poisson effect and the resulting narrowing in finite element analysis (FEA) models of veins. Furthermore, when comparing FEA models of veins and arteries, we see that the effect is much more pronounced (both in the magnitude of longitudinal strain and narrowing of the adjacent vessel) in veins compared to arteries due to the higher Young's modulus (stiffness) of veins compared to arteries. These FEA findings are further supported by clinical data considering the correlation between the degree of external iliac vein (EIV) narrowing and the relative common iliac vein (CIV) diameter increase. Furthermore, the Poisson effect is likely exacerbated in post-thrombotic veins due to the relatively higher Young's modulus of post-thrombotic fibrous veins compared to normal healthy veins.

[0016]

[0052] As a result, application of direct radial force from a stent at a venous stenosis is not an ideal treatment due to redistribution of applied radial force in the longitudinal direction and the resulting incomplete expansion of the vein, i.e., stenosis of the vein adjacent to the stent placement. Utilizing an endovascular device that actively controls the longitudinal aspects of the vein in addition to radial expansion may improve overall luminal gain and improve outcomes. Controlling longitudinal biomechanical forces not only prevents transmitted forces to adjacent venous segments, but also improves direct application of therapeutic forces to the diseased venous segment, improving luminal gain in the diseased segment. Active longitudinal control with longitudinal tensile strain in the treated segment not only reverses the compression seen with current treatment options, but also applies longitudinal strain directly to the diseased segment (in addition to radial expansion). Through these biomechanical methods, active control and redistribution of longitudinal forces results in an overall increase in venous lumen volume and improved venous flow.

[0017]

[0053] One possible method to add both radial and longitudinal expansion is the use of stents with auxetic geometries. Auxetic stents are defined by geometries that exhibit a negative Poisson's ratio. Poisson's ratio is the signed ratio of transverse strain to longitudinal strain. By definition, geometries with negative Poisson's ratios lengthen upon radial expansion. Auxetic stents using these geometries provide relaxation rather than tension to adjacent vein segments, improving overall luminal volume gain in stented and non-stented segments. Terms such as "auxetic" and "Poisson's ratio" are commonly used to describe material properties, but in this document these terms are used to describe the properties of the geometry of the stent design and not necessarily the material or materials from which it is manufactured.

[0018]

[0054] The following description relates to stents and methods of use that can be used to treat venous stenosis. Specifically, the stents are auxetic in nature, and expand in length longitudinally (or axially) as they expand radially.

[0019]

[0055] 1A-4 show various views of an auxetic stent 100 that can be used to treat venous stenosis with improved luminal gain. As shown in FIGS. 1A and 1B, the stent 100 is in its compressed form, its most compact, tubular configuration with a hollow center 110. In FIG. 1C, a cross section of the stent 100 is shown to illustrate the arrangement of the various cells 102 that comprise the stent 100. Each cell is composed of a series of interconnected struts 101, as described herein with respect to FIG. 6. The struts can be folded over one another to allow the stent 100 to be compressed or expanded. Additionally, the particular configuration of the struts provides the stent 100 with auxetic properties, as described further herein.

[0020]

[0056] FIG. 1C shows four cells interconnected widthwise. It will be understood by those skilled in the art that these cells are wound around the circumference with end 104 joined to end 106 to form the tubular configuration shown in FIG. 1A and FIG. 1B. Furthermore, in addition to being joined widthwise, cells 102 can be joined lengthwise via end 108 to expand the length of stent 100 rather than increasing its diameter. By joining cells 102 to both ends 104, 106, 108, stent 100 can be constructed to any diameter and length required for a given application. As can be seen in FIG. 1B and FIG. 1C, the joining of the various cells effectively gives stent 100 a mesh configuration due to its interconnected cells.

[0021]

[0057] The number and / or size of the cells 102 determine the overall compressed size and dimensional properties of the stent 100. For a given size of cells 102, a greater number of cells 102 will result in a larger diameter of the stent 100, and a smaller number will result in a smaller diameter of the stent 100. Similarly, for a given number of cells 102, larger or smaller cells 102 will result in a stent 100 with a larger or smaller diameter as well. The arrangement of the various folded struts 101 contributes to the auxetic properties of the stent 100, i.e., the degree to which the stent 100 stretches axially as it expands radially. The number of cells 102 and the arrangement of the struts 101 further contribute to the maximum amount of expansion or compression that the stent 100 can provide.

[0022]

[0058] FIG. 2 shows the example stent 100 after expansion. In the illustrated embodiment, using the dimensions of the various components of the example stent 100 shown in FIG. 1B and FIG. 1C, e.g., 2.5 mm diameter, the stent 100 is expanded to a diameter of 14 mm. As can be seen, the various struts unfold during expansion. As they unfold, some struts 202, 204 reorient from a horizontal position (relative to the other struts and with reference to the orientation of the figure) to a more vertical position. The struts 202, 204 are interconnected by horizontal struts 208 that are stationary relative to a given cell. This then forms an expansion space 210 in which the interconnected cells of the stent 100 form a lattice. Furthermore, as the struts 202, 204 unfold to a vertical position, they push the horizontal struts 206 on either side of each cell outward from the space 210. This effectively expands the width of each cell along the direction of the horizontal struts 206, 208. As can be seen by comparison with the compressed configuration of stent 100 shown in FIG. 1A, the forced disengagement from struts 206 increases the overall axial length of the stent 100 as it expands radially in accordance with the auxetic properties of the stent 100.

[0023]

[0059] FIG. 3 shows the stent 100 in a slightly relaxed configuration, with the diameter reduced from 14 mm to 12 mm. The primary relaxation points are the spaces 302 between the struts 202, which are of reduced width compared to the embodiment shown in FIG. 2. As a result, the horizontal struts 206 move towards the spaces 302, which results in a contraction in the width of the stent 100 in the axial direction. As described further herein, the horizontal struts 208 may be deformable, and thus may shorten the axial length of the stent 100 in its fully expanded configuration, such as by axial compression. When so compressed, the stent 100 in its 14 mm expanded state may have substantially the same axial length as the stent 100 in its slightly relaxed 12 mm configuration.

[0024]

[0060] 4 shows stent 100 in a fully compressed configuration having a diameter of about 2.5 mm. As in Figures 1A and 1B, all struts in stent 100 return to a collapsed configuration with a corresponding axial length of stent 100 at a minimum.

[0025]

[0061] The stent 100 can be made from any material suitable for use in its intended application. In embodiments intended for medical applications, such as implantation or placement in a blood vessel, such as a vein, the stent 100 can be made from a suitable biologically inert material or materials, for example, a metal alloy, such as stainless steel or nitinol, or a polymer. The material can be selected for its elastic or plastic properties, taking into account its response to expansion and relaxation. Some materials, such as metal types, can undergo various treatments to change the elasticity point to accentuate the plastic or elastic properties. For example, in medical applications, the stent 100 needs to retain size after expansion to ensure that the vein is not occluded, so a more plastic and deformable material may be desired over an elastic material. Such materials show little or no reduction in size after expansion. Other materials can retain a moderate degree of elasticity after plastic deformation to allow for stent adjustment after initial placement. Expansion of the stent 100 within the patient's body can be achieved using well-known medical techniques, such as an inflating endoscope or catheter balloon.

[0026]

[0062] In one embodiment, the stent 100 may be formed from Nitinol, an intermetallic compound having approximately 50.8 atomic percent nickel and the remainder titanium. Nitinol has the unique properties of shape memory and superelasticity. In this embodiment, the stent 100 takes advantage of the material's ability to withstand unusually high levels of strain (up to 8% or more) without experiencing plastic deformation. The material may have an unusually significant hysteresis effect in its stress-strain relationship (compared to other available materials). When loaded, the stress is relatively high. As the load continues to increase, the stress response eventually reaches an upper plateau (UP) where a phase change from austenite to martensite occurs. When the material is unloaded, the stress becomes relatively low and reaches a lower plateau (LP) where the material transforms from martensite to austenite. The magnitude of the difference between the UP and LP stresses depends on the material composition, thermal history, and processing history.

[0027]

[0063] In some embodiments, the transition temperature of the material, known as the austenite finish (Af) temperature, is set between 10°C and 37°C. Once processed into a shape in this manner, the material can be plastically deformed at temperatures below 37°C, but will return to the processed shape when the temperature reaches the Af temperature. Using such principles, in another embodiment, the stent 100 can be manufactured at a large diameter (Figure 2) and compressed to a small diameter (Figure 4) while simultaneously shortening its axial length for loading into a delivery catheter. If the stent 100 is manufactured from Nitinol, this radial compression is resisted by UP stress. When such a stent is released from the delivery catheter and / or heated by the patient's body temperature, the stent will radially recover to an intermediate diameter (e.g., as shown in Figure 3) controlled by the vein in which it is placed, while simultaneously increasing in length. This recovery is controlled by LP stress. Thus, the heat treatment can be preferentially selected to achieve the desired Af temperature and LP stress suitable for applying the desired radial and axial forces to the vein.

[0028]

[0064] It should be understood that the selection of materials for manufacturing the stent 100 and / or treatment processes for the materials or stent 100 can be performed to achieve desired performance characteristics of the stent 100. For example, a given embodiment of the stent 100 can be manufactured and treated to change shape primarily in a plastic mode, where the change in shape of the stent 100 is maintained without expanding or contracting, thereby delivering minimal ongoing forces to the surrounding vessel. Such an embodiment may be expanded (e.g., via a catheter balloon during insertion) such that the surrounding vessel wall is under tension and exerts a force against the stent 100, which resists but does not compress significantly and does not exert additional force or stress on the vessel. In such an embodiment, by controlling the amount the stent 100 is expanded, the amount of tension exerted on the vessel wall can be fine-tuned (e.g., minimized or eliminated) and adjusted during insertion of the stent 100. Furthermore, if the stent 100 can be expanded to different degrees at different locations, such a stent 100 can vary the tension on the vessel wall over the length and diameter of the stent 100.

[0029]

[0065] In another embodiment, the stent 100 is manufactured / treated with elastic properties to provide a predetermined amount of force against compression so that the vessel wall expands under tension and the tension of the vessel wall balances the force exerted by the stent 100. Further treatments can allow the stent 100 to exhibit varying degrees of plasticity / elasticity over its length, for example, one end or one section of the stent 100 can provide an outward force through elasticity, while the other end or another portion of the stent 100 can provide a second, different outward force and / or can only provide plastic deformation, with no or little outward force. Such configurations can be manufactured, for example, by treating or manufacturing each cell individually to achieve desired performance characteristics, and then assembling the stent 100 from various cells treated in various ways to achieve a stent 100 with variable or selective elastic / plastic properties over its length and diameter.

[0030]

[0066] 5 and 6, an example cell 500 that may be used with the stent embodiments disclosed herein is shown. FIG. 5 shows the cell in its closed, unexpanded configuration. The cell 500 is similar in configuration and structure to each of the cells 102 shown in FIGS. 1A-1C. FIG. 6 shows various components of the cell 500. The cell 500 includes a first strut 602 and a second strut 604. The first strut 602 and the second strut 604 each include a first segment 602a and a second segment 602b, and a first segment 604a and a second segment 604b, respectively.

[0031]

[0067] The first and second segments 602a, 602b are defined by flexible joints 606, and the first and second segments 604a, 604b are defined by flexible features 608. In an embodiment, the flexible joints 606, 608 are curved sections formed in each of the first and second struts 602, 604. In other embodiments, the flexible joints 606, 608 may be formed separately to join the respective first and second segments 602a, 602b, 604a, 604b to one another and may be formed from the same or different materials as each of the various segments. In yet other embodiments, the flexible joints 606, 608 may be fabricated from a material selected to be elastically flexible, while the various struts and segments may be fabricated from a relatively rigid material that does not or barely undergoes plastic deformation. Alternatively or additionally, the material may be treated to change its elasticity to accentuate either plasticity or elasticity depending on the needs of a given implementation. For example, in some embodiments, all of the segments 602a, 602b, 604a, 604b may be manufactured from a single material along with the flexible joints 606, 608, e.g., the joints 606, 608 are treated to accentuate plasticity and the struts 602, 604 are treated to accentuate elasticity.

[0032]

[0068] The first strut 602 and the second strut 604 are coupled to one another by a cross member 610, which in the illustrated embodiment is coupled to the first segment 602a at joint 612a and to the first segment 604a at joint 612b. The joints 612a, 612b may be essentially similar to the flexible joints 606, 608 or may be more rigid. As will be appreciated by one of ordinary skill in the art, in the illustrated embodiment, the joints 612a, 612b may be implemented in a more rigid manner since they typically do not undergo the same amount of flexing as the flexible joints 606, 608. As seen in FIG. 6, the joints 612a, 612b are affixed proximate to the first segment ends 626, 628 and distal from the flexible joints 616, 622, respectively.

[0033]

[0069] In an embodiment, the joint members 614, 620 are attached to the second segments 602b, 604b at joints 616, 622, respectively. The joints 616, 622 may be of a similar type to the joints 612a, 612b, so long as they do not experience the same degree of deflection as the flexible joints 606, 608. As can be seen in the illustrated embodiment, the joints 616, 622 are placed relatively close to the flexible joints 606, 608 and relatively distal from the second segment ends 630, 632, respectively. In other words, as seen in FIG. 6, the joints 616, 622 are not positioned equidistant between the flexible joints 606, 608 and the second segment ends 630, 632, but rather are closer to the flexible joints 606, 608 and therefore further from the second segment ends 630, 632. The arrangement of the various joints 612a, 612b, 616, 622, and therefore the placement of the cross members 610 and joint members 614, 620 relative to the struts 602, 604, determines the overall geometry of the cell 500, which in turn determines the amount of axial expansion exhibited by the cell 500 upon expansion. As can be seen in the illustrated embodiment, moving the various joints 612a, 612b, 616, 622 closer to the centers of the first segments 602a, 602b and second segments 604a, 604b, respectively, results in a lesser degree of axial expansion, and similarly, moving the various joints farther from the respective centers results in a greater degree of axial expansion.

[0034]

[0070] As seen in the example illustrated in FIG. 6, in some embodiments, joint members 614, 620 are attached at joints 616, 622, respectively, forming acute angles 634, 636. Similarly, cross member 610 is attached at joints 612a, 612b, respectively, forming acute angles 638, 640. As can be seen, angles 634, 636, 638, 640 are acute in the sense that they are less than 90 degrees. In some embodiments, angles 634, 636, 638, and / or 640 are each formed from substantially bent curves that contact the respective first and second members 602, 604 (at joints 612a, 612b, 616, and / or 622) in a substantially perpendicular orientation and then bend to form initially parallel sections between the respective joint members 614, 620, cross member 610, and first and second members 602, 604. Junction members 614, 620 and / or cross member 610 may then diverge from first member 602 and second member 604 distal to angles 634, 636, 638, and / or 640. Forming angles 634, 636, 638, and / or 640 as acute angles can provide several benefits to the cross member stent design at the insertion site, namely, facilitating successful loading / crimping of the stent onto the delivery catheter after fabrication (e.g., laser nitinol cutting) and expansion, facilitating axial / longitudinal stent compression and elongation (see FIGS. 7 and 8), facilitating radial expansion from the loaded / crimped state, and minimizing stress / strain at the cross member insertion site while facilitating the aforementioned benefits and reducing the long term risk of stent fracture.

[0035]

[0071] As shown in the various figures, each cell 500 can be combined with adjacent cells 500 to form the stent 100. Each cell 500 is joined to the other cells via first segment ends 626, 628, second segment ends 630, 632, and junction member ends 618, 624. Referring to Figures 1A, 1C, and 4 for a general arrangement of cells in the stent 100, it will be recognized that each first segment end 626, 628 is attached to a corresponding second segment end 630, 632, respectively, of an adjacent cell 500. The attachment of each first segment end 626, 628 to the adjacent second segment end 630, 632 effectively forms two pairs of flexible junctions. These second flexible junctions perform the same function as the flexible junctions 616, 622 across the stent 100 and therefore may be configured identically to the flexible junctions 616, 622. It will be appreciated that the flexible junctions 616, 622, along with the second flexible junctions, play a primary role in defining the expansion and crimp behavior of the stent 100 in embodiments.

[0036]

[0072] The cells are joined along the axial direction via joint member ends 618, 624, which are attached to corresponding joint member ends 624 of the adjacent cell 5000. In the illustrated embodiment, this connection effectively forms a second cross member similar in shape to cross member 610 through the combination of joint member 614 and joint member 620 of the adjacent cell 5000. This second cross member may thus be of similar construction to cross member 610, and the connection between joint member ends 618, 624 may be configured or of a type to result in a second cross member that is substantially identical to cross member 610 in terms of performance and material properties. For example, joint member ends 618, 624 may be welded or soldered together.

[0037]

[0073] As will be appreciated, both the axial and circumferential bonded cells 500 (for a tubular stent) can be repeated to provide a stent 100 of any diameter and axial length suitable for a given intended application. Additionally, while the stent 100 has been described as being composed of a number of separate cells 500 bonded together, this is merely one method of manufacture and is not intended to suggest a preferred method of manufacture, but is described to help explain the general structure of the stent 100. It will be appreciated that the stent 100, or portions thereof, can be manufactured as a single unit by rolling together one or more strands of suitable material, such as wire, or via other pieces, larger or smaller, using any suitable manufacturing method, such as welding, soldering, bonding, twisting, casting, or other methods later known or developed.

[0038]

[0074] To allow for further control of the axial expansion of stent 100 beyond the natural expansion resulting from the configuration of each cell 500, cross member 610 and second cross member (collectively referred to herein as the "cross member" or "cross members") formed from junction members 614, 620 can be configured to plastically deform by bending when axial compression or tension is applied to at least partially expanded stent 100. This deformation allows the axial length of stent 100 to be adjusted while maintaining a constant expanded diameter, i.e., without having to radially expand or crimp stent 100. An example of this operation is shown in Figures 7 and 8.

[0039]

[0075] 7 shows a cell 500 from a stent 100 that has been radially expanded while keeping its axial length constant. The same configuration can be achieved by axially compressing the stent 100 while keeping the radial diameter constant. In the illustrated embodiment, the cross members 710 and corresponding joining members 714, 720 are imparted with curves that result in a relatively short axial length of the stent 100. These curves can be imparted by axially compressing the stent 100 while keeping the radial diameter constant.

[0040]

[0076] In the embodiment shown in FIG. 8, the cross members 810 and corresponding joint members 814, 820 are substantially straight and uncurved, thus maximizing the axial length of the stent 100. Such straightening can be accomplished to the limits of the cross members by axially expanding or stretching them while keeping the radial diameter of the stent 100 constant, provided there is sufficient curvature in the joint members 814, 820 and / or the cross members 810. As will be described below, straightening the cross members results in a greater distance 802 measured between the flexible joints than the corresponding distance 702 in the embodiment of FIG. 7 where the stent 100 is axially compressed. Depending on the configuration and structure of the cell 500 that contains a given stent 100, the radial diameter can either remain constant without mechanical assistance during application of axial pressure for stretching or compression, or require mechanical support such as a balloon or other expander to maintain the radial diameter.

[0041]

[0077] While Figures 1A-8 show cells with reentrant orthogonal configurations, Figures 9 and 10 show alternative embodiments of cells including stents. Figure 9 shows a plurality of cells each with a rota-chiral diamond shape. Figure 10 shows a plurality of cells each with a rota-chiral orthogonal configuration. As can be seen, the diamond configuration results in ring structures aligned in a staggered arrangement, while the orthogonal arrangement results in ring structures aligned in a grid arrangement. Various configurations can provide performance differences that are useful for different applications, for example, some configurations are more suitable for substantially curved vessels, while other configurations are more suitable for substantially straight vessels. In either configuration, the axial length is adjustable while keeping the radial diameter constant, but the mechanism for adjusting the axial length can include application of rotational or circumferential forces rather than axial compression or stretching.

[0042]

[0078] In FIG. 11, the application of stent 100 in a vascular context is shown in comparison to the application of a non-auxetic stent. Panels (a) and (b) show the application of a non-auxetic stent. In panel (a), the stent is put into place and radial expansion is initiated. As the expanded stent is of shorter length than the non-auxetic stent, as indicated by the arrows, the radial expansion in the non-auxetic stent results in a corresponding decrease in axial length, as shown in panel (b). This shortening, combined with the possibility that the expanded stent may adhere or pull the vessel wall into a compressed configuration as the stent shortens, may strain adjacent portions of the vessel, reducing the vessel diameter in the adjacent portions due to the nature of vascular tissue and the transmission of mechanical stresses. This undesirable decrease in vessel diameter may result in insufficient treatment of the diseased segment and subsequent vessel occlusion, requiring further medical treatment.

[0043]

[0079] Panels (c) and (d) show the use of stent 100 according to various embodiments herein. In panel (c), auxetic stent 100 is deployed and then expanded. In accordance with the properties of stent 100, the stent lengthens axially as it expands radially, as shown in panel (d), where the expanded stent 100 is axially longer than the non-auxetic stent in panel (c). As stent 100 expands, it does not strain adjacent vessel segments so as not to cause the same diameter reduction caused by a non-auxetic stent. As a result, the use of an auxetic stent can improve luminal gain and reduce or completely eliminate the possibility of subsequent vessel occlusion occurring adjacent to the stented vessel segment. FIG. 34 shows the narrowing of the adjacent vein wall resulting from the deployment and expansion of a non-auxetic stent into the vein, as shown in panel (b), in cross section, along with the stresses applied to various portions of the vein wall.

[0044]

[0080] 12 provides operations of an example method 1200 for using an auxetic stent such as stent 100 to treat a venous stenosis. The operations of method 1200 can be performed in whole or in part using stent 100. In operation 1202, the vessel segment requiring treatment is located and evaluated, along with the properties of any adjacent vessel segments. After evaluation, in operation 1204, a stent having an appropriate diameter and length and having appropriate auxetic properties, e.g., the correct or ideal amount of axial expansion versus radial expansion, is selected and then placed in the vessel segment to be treated. In operation 1206, the stent is then radially expanded an appropriate amount to relieve the obstruction of the vessel segment and ensure proper axial expansion.

[0045]

[0081] Finally, in operation 1208, the axial length is appropriately adjusted to relieve stress on adjacent vessel segments, prevent narrowing of the diameter of the adjacent vessel segments, and improve lumen gain in the stented vessel segments. If the vessel is curved, the axial force can be applied asymmetrically, e.g., more at one circumferential portion, to compress or elongate only a portion of the cross members of the stent 100, thereby bending the stent 100 to conform to the shape of the vessel while preventing undesired narrowing of the adjacent vessel diameter. As described above, the axial force can be a compressive force to bend the cross members to shorten their axial length, or an elongation force to straighten the cross members to lengthen them axially, or a combination of compression and elongation at different circumferential portions of the stent 100, to place the stent 100 in a curved shape in an expanded state.

[0046]

[0082] It will be appreciated that in the disclosed embodiments, the stent 100 is operable in a range of diameter configurations including a compressed diameter suitable for delivery into a vessel, a fully expanded diameter that may be equal to or greater than the maximum anticipated diameter of the target vessel, and any of a continuous range of intermediate diameters between these two extremes. In typical use, when the stent 100 is expanded from a compressed state at the intervention site, it initially contacts the vessel at an intermediate diameter. The diameter of the first contact may be smaller than the desired diameter for optimal treatment outcome. Thus, after initially contacting the vessel, the stent 100 may be further expanded in diameter to achieve the desired vessel lumen diameter. This additional expansion is driven by the desired elastic or superelastic properties of the stent 100 and may be further assisted by ancillary interventions such as balloon venoplasty. Given the auxetic properties of the stent 100, such additional expansion is accompanied by a concomitant increase in axial length, which may be controlled or limited as described above.

[0047]

[0083] It will be further appreciated that alternative embodiments of auxetic stents can be readily generated based on the geometry of the unit cells (as shown in Figures 5 and 6) by varying the dimensions of the unit cells and the number of unit cells circumferentially connected to form a tubular configuration. In various embodiments, the number of cells circumferentially connected to form a tubular configuration for the stent can be varied between 4 cells and 50 cells, with cell sizes to produce stent diameters of 1 mm to 100 mm after radial expansion. Similarly, unit cells can be combined axially to produce stents of different lengths. Thus, the approach described herein can be used to generate stents suitable for deployment in vessels of various sizes for different applications or mechanical effects.

[0048]

[0084] 13 and 14, in some embodiments, the benefits of axial extension during expansion can be further enhanced by the use of axial engagement protrusion features 1401. One or more of such features may be circumferentially aligned at one or both ends of the auxetic stent, as shown in the compressed state at 1301 and the expanded state at 1401. While FIGS. 13 and 14 show isolated sections of the complete stent 100 with protrusions located at both ends, as can be seen, cells adjacent to other cells (e.g., not at the ends of the stent) are devoid of protrusion features. However, such protrusion features can be located within the body of the stent in any number or arrangement to achieve the desired engagement with the vessel. When the auxetic stent 100 is expanded, these features may be designed to protrude at an angle, as seen in FIG. 14, so that the tips of the protrusions rise from the other features and therefore contact the vessel sooner than the body of the stent. Moreover, such protruding projections help provide contact between the stent 100 and the vessel during the additional expansion described above, commonly referred to as post-dilation. The presence of projections improves axial coupling between the stent and the contacted vessel. Thus, such projections help transmit the axial elongation of the stent directly to the vessel, avoiding axial slippage between the stent and the vessel, and maximizing the axial tensile force imparted to the vessel at the contact area with the stent. Furthermore, such projections promote or otherwise aid in longitudinal coupling with the vessel wall, helping to hold the expanded stent in place. As the stent 100 expands axially in response to radial expansion or by direct stretching, the projections act to tension the vessel wall of the stented vessel portion, while relieving tension in the vessel wall of the vessel portion adjacent to the stent 100, helping to prevent stenosis. Additionally, in other embodiments, variations in protrusions can be used for longitudinal bonding, such as roughening the surface of the stent, inclusion of different sized protrusions such as microbarbs and / or macrobarbs, or a combination of the two, and / or varying the texture of the surface of the stent, or a combination of one or more of these.

[0049]

[0085] Auxetic stent animal experiment

[0050]

[0086] procedure

[0051]

[0087] Figure 15 shows an example stent 1500 consisting of a set of 10 cell, 14 mm diameter self-expanding Nitinol auxetic stents with protrusions on the proximal and distal stent ends similar to the embodiment shown in Figure 14. Figure 16 shows the auxetic stent 1600 in an expanded configuration with an expanded stent length of 7.7 cm and a restrained stent length within the catheter of 6.0 cm along with a catheter loaded stent 1602. As shown in Figure 16, the 14 mm diameter self-expanding Nitinol auxetic stent was loaded into an 18 gauge Hawkins needle using liquid nitrogen and then loaded into a 14 French catheter.

[0052]

[0088] 17-19B show experimental results of deploying an auxetic stent, such as example stent 1500, in an animal. Ultrasound-guided access was obtained to both femoral veins of an anesthetized pig. A wire was advanced through the right femoral vein into the inferior vena cava (IVC) and an 18 French sheath was placed. The stent was loaded into the sheath using an 18 gauge introducer Hawkins needle and the introducer needle was removed. A catheter was advanced into the right common iliac vein using a 14 French modified dilator and the stent was deployed using the unsheathing technique. Repeat venograms were performed. The stent was then angioplastied with a 6 cm long 14 mm diameter balloon. Repeat venograms were performed.

[0053]

[0089] A 7 French sheath was then placed in the left femoral venous access. Using the technique previously described, a radiofrequency ablation catheter was advanced into the left common iliac vein and external compression was applied. Serial ablation was performed at 40 second intervals until stenosis of 70% or greater was achieved. Repeat venograms were performed. An 18 French sheath was advanced into the left common iliac vein and an auxetic stent was positioned centrally over the left common iliac vein stenosis. Repeat venograms were performed. Balloon angioplasty of the stent was performed with a 12 mm diameter balloon followed by a 14 mm diameter balloon. A second auxetic stent was deployed with expansion below the inguinal ligament. Repeat venograms were performed. The stent was then ballooned and angioplasty in the stent was performed with a 12 mm diameter balloon. Venograms were performed with the left hip in mid-flexion. A third auxetic stent was deployed through the left femoral venous access extending from the IVC into the left common iliac vein. The IVC and left iliac stent were inflated with a 14 mm diameter balloon. A final set-up venogram was performed.

[0054]

[0090] In another animal, ultrasound-guided access was obtained in the right femoral vein. A baseline venogram was performed. Using the technique described above, a radiofrequency ablation catheter was advanced into the left common iliac vein and external compression was applied. Serial ablations were performed at 40 second intervals until stenosis of 70% or greater was achieved. Venograms were repeated. A currently commercially available 14 mm diameter stent (currently commercially available stent) was deployed in the right common iliac vein. Venograms were repeated. Balloon angioplasty of the stent was performed with a 12 mm diameter balloon followed by a 14 mm diameter balloon. A final repeat venogram was performed.

[0055]

[0091] result

[0056]

[0092] Figure 17 shows a venogram of a normal iliac vein prior to stent deployment, with the pre-stent vein diameter labeled. An auxetic stent was deployed in the right common iliac vein without difficulty. The stent deployed by expanding radially against the vein wall. After expanding an auxetic stent with a 14 mm diameter balloon in a healthy right common iliac vein, the vein diameter increased from 9 mm to 14.1 mm, a 56.7% increase in vein diameter. The diameter of the vein adjacent to the stent was 9.9 mm prior to the intervention and 11.2 mm after stent placement and ballooning. This represents a 13.1% increase in adjacent vein diameter despite the absence of direct intervention. Figure 18 shows the same area after deployment, angioplasted with a 10-cell, 14 mm auxetic stent, 14 mm x 6 cm balloon.

[0057]

[0093] Stenosis of 70% or greater was successfully created in the common iliac vein in both auxetic and currently available stent animal models. After placement of the currently available stent, the diameter increased to 76.5% of the native vein diameter. After ballooning the currently available stent, the diameter increased to 93.8% of the native vein diameter. After placement of the auxetic stent, the diameter increased to 70.1% of the native vein diameter. After ballooning the auxetic stent with a 14 mm diameter balloon, the diameter increased to 174.7% of the native vein diameter.

[0058]

[0094] 19A and 19B show venograms taken in hip extension and 90 degree hip flexion with the auxetic stent in place. Annotated measurements of vein diameter confirmed that the stent maintained normal venous flow and diameter.

[0059]

[0095] Figure 35 shows venograms of a different vein at each step of the procedure. The left venogram shows a normal vein with a diameter of 9.4 mm. The middle venogram shows venous stenosis after endovenous radiofrequency ablation. The right venogram shows the ablated vein with an auxetic stent in place, which restores the diameter to 9.5 mm.

[0060]

[0096] The use of stents may have different results between veins and arteries due to the relatively thicker and more robust walls of arteries, which are required to handle higher arterial blood pressure. Figure 36 shows two graphs from a finite element analysis vascular model, showing higher relative adjacent vessel diameter reduction during angioplasty in veins versus arteries (left), and higher vessel wall longitudinal displacement / strain during angioplasty in veins versus arteries (right). Thus, the use of auxetic stents in the venous context produces more dramatic results compared to arteries.

[0061]

[0097] Figure 37 shows venograms comparing the results of deployment in a vein of an auxetic stent (left) and a non-auxetic stent (right). As can be seen, the auxetic stent of the illustrated embodiment results in relatively little stenosis of the vein adjacent to the stent placement (~9.5mm), while the non-auxetic stent shows substantial stenosis of the adjacent vein wall (~5.9mm). Finally, Figure 20 shows direct surgical visualization of the inferior vena cava after placement of a barbed auxetic stent. As can be seen, no vein damage is evident on direct inspection.

[0062]

[0098] conclusion

[0063]

[0099] Auxetic self-expanding stents successfully deployed and expanded both healthy and stenosed veins, achieving luminal gain up to the balloon diameter without narrowing adjacent veins. In contrast, currently available stents failed to achieve luminal gain to the balloon diameter. These comparative findings confirm that luminal gain can be improved over closed cell stents with the use of auxetic stents. Furthermore, imaging of auxetic stented veins with the hip in expanded and flexed positions confirmed vessel patency in both positions, demonstrating the flexibility of the stent.

[0064]

[0100] Referring to FIG. 21, further aspects of using a stent constructed from auxetic materials compared to non-auxetic materials are shown. Part a shows the result of applying pressure to a point on a section 2102 of non-auxetic material. As can be seen, because the non-auxetic material lacks the folded configuration present in the cells of an auxetic stent, the entire section of material curves only along the longitudinal axis, while the material does not substantially deform laterally. This results in an overall bent or arched shape of the piece. The lack of lateral deformation may in some scenarios prevent a stent constructed from such non-auxetic materials from properly conforming into an irregular vein. In contrast, part b shows the result of applying pressure to a point on a section 2104 of auxetic material. As can be seen, the material deforms and expands in both the longitudinal and lateral directions due to the folded configuration of the constituent cells, forming a dome or bump rather than an arc. This multi-dimensional deformation allows stents constructed from such auxetic materials to better and / or more precisely conform to irregular features in a vein or other blood vessel.

[0065]

[0101] FIG. 22 illustrates the multi-dimensional deformation of auxetic materials in a vascular context. A venogram shows stent 2200 in place within a blood vessel. Following expansion, stent 2200 conforms to the asperities 2202, 2204 by expanding to form a dome shape, similar to that shown in FIG. 21 subview b. This complete expansion helps ensure that full vessel opening and blood flow is achieved. If a non-auxetic material were used, the stent would not fully expand and would not conform to any of the asperities 2202, 2204.

[0066]

[0102] It will be further understood that in the disclosed embodiments, the stent 100 may be placed in anatomical structures that are morphologically similar to, but distinct from, blood vessels such as veins or arteries to facilitate patency of said anatomical structures. Thus, the various disclosed embodiments provide a more general method of treating stenosis in a mammalian lumen, which includes implanting the stent 100 described herein into a lumen, duct, or vessel in need thereof. The term "stenosis" as used herein refers to an abnormal narrowing or constriction of a lumen, duct, or other cavity in the body that affects the normal passage of materials (such as blood, air, food, feces, lymph, urine, saliva, bile, etc.) through the vessel, duct, or cavity. The term "implantation" as used herein refers to placing a stent, as described herein, into a location within a duct, duct, or cavity experiencing stenosis and expanding the stent to treat or reduce the stenosis.

[0067]

[0103] Exemplary non-venous and non-arterial applications include implantation into the bile duct, genitourinary tract, gastrointestinal tract, tracheobronchial structures, sinuses, salivary glands, ducts, and lymphatics. Additional applications include use in surgical procedures such as surgical enterosteotomies, surgical arteriovenous fistulas and grafts, and surgical anastomosis of any two structures in the body.

[0068]

[0104] Also possible is a method of treating a stricture in the cystic duct or common bile duct in a human, comprising implanting a stent as described herein into the stricture in the cystic duct or common bile duct in a human in need thereof. A method of treating a bile duct disease in a human, where the bile duct disease is associated with a stricture in the cystic duct or common bile duct, can comprise implanting a stent as described herein into the stricture in the cystic duct or common bile duct in a human in need thereof. As used herein, "bile duct disease" or "biliary tract disease" refers to diseases affecting the bile duct, gallbladder, and / or other structures involved in the production and transport of bile, including chronic or acute cholecystitis, cholangitis, choledocholithiasis, cholangiocarcinoma, benign biliary tumors, ampullary tumors, Mirizzi syndrome, and AIDS cholangitis.

[0069]

[0105] Stents identical or similar to stent 100 (or other embodiments herein) used in treating strictures of the cystic or common bile duct or in treating biliary tract disease may be about 1 mm to about 30 mm in diameter and about 5 mm to about 200 mm in length, fully expanded (particular stent measurements for particular uses herein are at full expansion of the stent, unless otherwise noted, and all diameters are outer diameters). In some embodiments, stents for biliary use may be about 5 mm to about 15 mm in diameter and about 20 mm to about 120 mm in length, fully expanded. In some embodiments, biliary stents may be about 5 mm to about 10 mm in diameter and about 20 mm to about 120 mm in length. Specific stents used for bile duct treatment include (diameter x length) 5mm x 20mm, 5mm x 30mm, 5mm x 40mm, 5mm x 50mm, 5mm x 60mm, 5mm x 70mm, 5mm x 80mm, 5mm x 90mm, 5mm x 100mm, 5mm x 110mm, 5mm x 120mm, 5mm x 130mm, 5mm x 140mm, 5mm x 150mm, 6mm x 20mm, 6mm x 30mm, 6mm x 40mm, 6mm x 50mm, 6mm x 60mm, 6mm x 70mm, 6mm x 80mm, 6mm x 90mm, 5mm x 100mm, 5mm x 110mm, 5mm x 120mm, 5mm x 130mm, 5mm x 140mm, 5mm x 150mm, 6mm x 20mm, 6mm x 30mm, 6mm x 40mm, 6mm x 50mm, 6mm x 60mm, 6mm x 80mm, 6mm x 90mm, 6mm x 100mm, 6mm x 110mm, 6mm x 120mm, 6mm x 130mm, 6mm x 140mm, 6mm x 150mm, 6mm x 20mm, 6mm x 30mm, 6mm x 40mm, 6mm x 50mm, 6mm x 60mm, 6mm x 70mm, 6mm x 80mm, 6mm x 90mm, 6mm x 100mm, 6mm x 110mm, 6mm x 120mm, 6mm 40mm, 6mm x 50mm, 6mm x 60mm, 6mm x 70mm, 6mm x 80mm, 6mm x 90mm, 6mm x 100mm, 6mm x 110mm, 6mm x 12 0mm, 6mm x 130mm, 6mm x 140mm, 6mm x 150mm, 8mm x 20mm, 8mm x 30mm, 8mm x 40mm, 8mm x 50mm, 8mm x 60m m, 8mm x 70mm, 8mm x 80mm, 8mm x 90mm, 8mm x 100mm, 8mm x 110mm, 8mm x 120mm, 8mm x 140mm, 8mm x 150m m, 10mm x 20mm, 10mm x 30mm, 10mm x 40mm, 10mm x 50mm, 10mm x 60mm, 10mm x 70mm, 10mm x 80mm, 10mm x Includes 90mm, 10mm× 100mm, 10mm×110mm, 10mm× 120mm, 10mm× 130mm, 10mm× 140mm, and 10mm×150mm.

[0070]

[0106] A method of treating a ureteral stricture in a human may comprise implanting a stent as described herein into a ureteral stricture in a human in need thereof.

[0071]

[0107] A stent the same as or similar to stent 100 (or another embodiment herein) used in treating a stricture in the human ureter or in treating a urinary tract disorder associated with a urethral stricture may have a diameter of about 1 mm to about 100 mm and a length of about 5 mm to about 500 mm (fully expanded state). In other embodiments, the urethral stent may include a diameter of about 1 mm to about 15 mm and a length of about 5 mm to about 500 mm. In other embodiments, the urethral stent may include a diameter of about 1 mm to about 12 mm and a length of about 5 mm to about 500 mm. In further embodiments, the urethral stent may include a diameter of about 1 mm to about 3 mm and a length of about 5 mm to about 500 mm. In further embodiments, the urethral stent may include a diameter of about 1 mm to about 2 mm and a length of about 5 mm to about 500 mm. The specific stents designed herein for ureteral implantation are available in the following diameter x length dimensions: 1 mm x 10 mm, 1 mm x 20 mm, 1 mm x 40 mm, 1 mm x 60 mm, 1 mm x 80 mm, 1 mm x 100 mm, 1 mm x 120 mm, 1 mm x 150 mm, 1 mm x 200 mm, 1 mm x 250 mm, 1 mm x 300 mm, 1 mm x 350 mm, 1 mm x 400 mm, 1 mm x 500 mm, 2 mm x 10 mm, 2 mm x 20 mm, 2 mm x 40 mm, 2 mm x 60 mm, 2 mm x 80 mm, 2 mm x 100 mm, 2 mm x 120 mm, 2 mm x 150 mm, 2 mm x 200 mm, 2 mm x 250 mm, and 300 mm. mm, 2 mmx 300 mm, 2 mmx 350 mm, 2 mmx 400 mm, 2 mmx 500 mm.

[0072]

[0108] A method of treating a stricture in the gastrointestinal tract of a human may comprise implanting a stent as described herein into the gastrointestinal stricture of a human in need thereof.

[0073]

[0109] A method of treating a stricture in the colon of a human may comprise implanting a stent as described herein into the stricture in the colon of a human in need thereof.

[0074]

[0110] A stent the same as or similar to stent 100 (or other embodiments herein) used to treat strictures in the gastrointestinal tract may have a diameter of about 1 mm to about 100 mm and a length (fully expanded) of about 5 mm to about 500 mm.

[0075]

[0111] A colonic stent the same as or similar to stent 100 (or other embodiments herein) may be about 20 mm to about 40 mm in diameter and about 20 mm to about 150 mm in length. In some embodiments, a colonic stent may be about 20 mm to about 35 mm in diameter and about 40 mm to about 140 mm in length. In other embodiments, a colonic stent may be about 26 mm to about 32 mm in diameter and about 40 mm to about 120 mm in length.

[0076]

[0112] A method of treating a stricture in the esophagus in a human may comprise implanting a stent as described herein into the stricture in the esophagus of a human in need thereof.

[0077]

[0113] An esophageal stent the same as or similar to stent 100 (or other embodiments herein) may be about 10 mm to about 25 mm in diameter and about 3 cm to about 20 cm in length. In some embodiments, a colonic stent may be about 15 mm to about 25 mm in diameter and about 5 cm to about 15 cm in length. In other embodiments, a colonic stent may be about 17 mm to about 23 mm in diameter and about 5 cm to about 15 cm in length.

[0078]

[0114] A method of treating a tracheobronchial stenosis in a human may comprise implanting a stent as described herein into a tracheobronchial stenosis in a human in need thereof.

[0079]

[0115] In some embodiments, the tracheobronchial stent may be about 5 mm to about 25 mm in diameter and about 10 mm to about 100 mm in length. In some embodiments, the tracheobronchial stent may be about 6 mm to about 22 mm in diameter and about 10 mm to about 100 mm in length. Specific examples of tracheobronchial stent sizes for use herein include about 8 mm x about 20 mm, about 8 mm x about 30 mm, about 8 mm x about 40 mm, 10 mm x about 20 mm, about 10 mm x about 30 mm, about 10 mm x about 40 mm, about 10 mm x about 60 mm, 12 mm x about 20 mm, about 12 mm x about 30 mm, about 12 mm x about 40 mm, about 12 mm x about 60 mm, about 12 mm x about 80 mm, 14 mm x about 20 mm, about 14 mm x about 30 mm, about 14 mm x about 40 mm, about 14 mm x about 50 mm, about 14 mm x about 60 mm, about 14 mm x about 80 mm, about ...60 mm, about 1 Examples of combinations of enlarged diameter x length include m x 60 mm, 14 mm x 80 mm, 16 mm x 20 mm, 16 mm x 30 mm, 16 mm x 40 mm, 16 mm x 60 mm, 16 mm x 80 mm, 18 mm x 20 mm, 18 mm x 30 mm, 18 mm x 40 mm, 18 mm x 60 mm, 18 mm x 80 mm, 20 mm x 20 mm, 20 mm x 30 mm, 20 mm x 40 mm, 20 mm x 60 mm, and 20 mm x 80 mm.

[0080]

[0116] A method of treating a salivary duct stenosis in a human may include implanting a stent as described herein into a salivary duct stenosis in a human in need thereof. Examples of salivary duct stents for use herein include those having a diameter of about 0.5 mm to about 3 mm and a length of about 1 mm to about 40 mm.

[0081]

[0117] In some embodiments, the geometry of the unit cells 500 of Figures 5-8 comprising an auxetic stent such as stent 100 can be modified to advantageously impart desired structural and mechanical properties to the stent upon deployment into a lumen. Similarly, the number of circumferentially and longitudinally arranged cells 500 can be selected to impart specific structural and mechanical properties to the stent. For example, various embodiments can use stents of various geometries at both the unit cell level and the stent device level to exhibit a range of radial and axial stiffness values. For a given embodiment, the selection of radial and axial stiffnesses governs the forces transmitted to the vascular structure in the radial and axial directions when the stent is deployed and expanded within the lumen of a vessel. Similarly, the geometry of the stent can be designed or tailored to produce a specific amount of expansion in the axial direction when a stent device embodying that geometry is radially expanded. In this manner, auxetic stents produced using the unit cell approach described herein can be used to actively control the degree of longitudinal force or stress experienced by the vessel in which the stent is expanded, both in the vessel wall immediately surrounding the expanded stent and in the vessel adjacent to the stent or upstream / downstream of the stent. Such active control of vessel wall mechanical stress using auxetic stent designs according to various embodiments disclosed herein can be used, for example, to mitigate undesirable narrowing of adjacent vessel diameters commonly observed with deployment of non-auxetic stents.

[0082]

[0118] In some embodiments, the structural properties and mechanical behavior of a stent device composed of unit cells, such as cell 500, constructed according to the schematic diagram of FIG. 6, can be tailored by varying the locations at which the individual struts are connected. For example, the locations of junctions 612a and 612b where cross member 610 joins first strut 602 and second strut 604 can be moved closer to or farther from the center of first segments 602a and 604a, respectively. Such design variations can be used to vary the radial and axial stiffness of the stent as well as the amount of change in axial length of the stent and the amount of longitudinal stress induced in the vessel wall when the stent is radially expanded. The thickness and / or cross-sectional area or material properties of the struts can also be varied to vary the structural properties and mechanical behavior of the cells. It is further understood that variations in the thickness and / or cross-sectional area or material properties of the struts will also manifest themselves in changes in the radial stiffness, axial stiffness, amount of change in axial length of the stent during radial expansion, and / or longitudinal stress induced in the vessel wall.

[0083]

[0119] Computer-aided design and mathematical modeling methods, such as finite element methods, can be used to characterize and compare the mechanical behavior of auxetic stent designs in accordance with embodiments described herein. Figures 23-28 show finite element modeling results for a circumferential side-by-side comparison of two example auxetic stent designs, each consisting of a circumferential ring of unit cells (such as cell 500), a first embodiment having 10 unit cells, and a second embodiment having 12 unit cells. To model the mechanical response (i.e., deformation, stress / strain, reaction forces) of each circumferential ring of 14 mm diameter unit cells, the following procedure was followed to simulate the construction as it was loaded: The model started from an unstrained configuration of 14 mm diameter and was (1) crimped to a diameter of 2.5 mm, (2) deployed (expanded) to a diameter of 12 mm, (3) axially stretched while constrained to 12 mm diameter, (4) returned to the unstretched state while constrained to 12 mm diameter, and (5) axially compressed while constrained to 12 mm diameter.

[0084]

[0120] Figure 23 shows the starting conditions for the finite element modeling simulations for the 10-cell and 12-cell models scaled to 14 mm in diameter. In Figure 24, both models are crimped to a diameter of 2.5 mm. The maximum strains in the fully crimped configuration (not shown) were calculated to be 7.6% for the 10-cell design and 6.9% for the 12-cell design. These strain levels are within the superelastic limits, indicating that both auxetic stent designs should fully recover to an inner diameter of 14 mm after being constrained to 2.5 mm while exposed to a temperature of 37°C.

[0085]

[0121] Figure 25 shows the configuration of the 10-cell and 12-cell stent designs as the models are deployed or expanded from the crimped configuration to a diameter of 12 mm (where 12 mm is intended to represent the final position of the stent in a properly expanded vein). The maximum strain of the models in this deployed position is approximately 2.4%. Note that the unit cell size is larger for the 10-cell design in the models in this deployed configuration.

[0086]

[0122] In Figure 26, the model is stretched axially while constrained to 12 mm diameter to characterize the axial stiffness of the entire structure in tension. These simulations show that the 12 cell design has more significant strut deformation than the 10 cell design. Figure 27 shows the model returned to the unstretched state while still constrained to 12 mm diameter. Figure 28 shows the model placed in axial compression while constrained to 12 mm diameter to characterize the axial stiffness of the entire structure in compression.

[0087]

[0123] FIG. 29 shows a comparison of the unit cell length of the 10-cell and 12-cell designs throughout the simulation. Time 0-1 represents crimping from 14 mm to 2.5 mm, time 1-2 represents deployment from 2.5 mm to 12 mm, time 2-3 represents axial stretching, time 3-4 represents return to the unstretched state, and time 4-55 represents axial compression. The results of the deployment during time 1-2 show that the 10-cell design embodiment modeled here is "more auxetic" than the 12-cell design embodiment because the unit cell length of the 10-cell design undergoes a greater expansion or elongation as the stent expands from the crimped state to the deployed state (i.e., as its diameter increases).

[0088]

[0124] FIG. 30 shows a comparison of unit cell length as a function of stent diameter corresponding to the loading regimens of FIG. 29. In an embodiment of a 10-cell design, as the model is scaled up from a 2.5 mm diameter to a 12 mm or 14 mm diameter, the unit cell length increases from 5.35 mm to 6.48 mm or 9.96 mm, respectively, corresponding to a 21% and 30% increase in length. In an embodiment of a 12-cell design, as the model is scaled up from a 2.5 mm diameter to a 12 mm or 14 mm diameter, the unit cell length increases from 5.35 mm to 6.19 mm or 6.51 mm, respectively, corresponding to a 16% and 22% increase in length. This mechanical behavior contrasts with that observed with conventional stents, which shorten (sometimes referred to in the art as "shortening") as the diameter increases during deployment.

[0089]

[0125] Figure 31 shows cell length versus total axial force for the same simulation of 10 and 12 cell embodiments, which can be used to obtain an estimate of axial stiffness from the slope of the curve. The axial stiffness of the 10 cell design was estimated to be 19 N / mm and the 12 cell design was estimated to be 37 N / mm. The greater axial stiffness of the 12 cell design is reflected in a smaller change in length as the stent is deployed.

[0090]

[0126] Figure 32 shows the normalized overall radial force versus model diameter for the same 10-cell and 12-cell simulations. These results show that the 10-cell design exerts a greater radial force than the 12-cell design. Compared to typical known peripheral stents, the auxetic design is predicted to have a lower resistive force and a somewhat higher chronic outward force.

[0091]

[0127] FIG. 33 shows the normalized total outward radial force versus time over the entire simulation for the same 10-cell and 12-cell embodiments. These results show the relationship between axial and radial stiffness. As seen in the illustrated embodiment, the outward radial force for the auxetic stent design increases as the stent is axially stretched and decreases as the stent is axially compressed. While this mechanical behavior is achieved in various embodiments of the disclosed auxetic stent designs, conventional (e.g., non-auxetic) stents typically provide the inverse of this mechanical behavior. In other words, for a typical conventional (non-auxetic) stent, the outward radial force decreases as the length increases due to stretching. Also note from these simulation results that the 10-cell design embodiment exhibits a greater outward radial force over the entire applied loading regime compared to the 12-cell design embodiment.

[0092]

[0128] It is understood that the configurations disclosed herein are exemplary in nature, and that these specific embodiments are not to be considered in a limiting sense, as numerous variations are possible. The subject matter of the present disclosure includes all novel and non-obvious combinations and subcombinations of the various systems and configurations and other features, functions and / or properties disclosed herein.

[0093]

[0129] The following claims particularly point out certain combinations and subcombinations that are deemed novel and non-obvious. These claims may refer to "an" element or "first" element or its equivalent. Such claims should be understood to include the incorporation of one or more such elements, and not to require or exclude two or more such elements. Other combinations and subcombinations of the disclosed features, functions, elements, and / or properties may be claimed through amendment of the claims or through the presentation of new claims in this or a related application. Such claims are considered to be within the subject matter of the present disclosure even if they are broader, narrower, equal, or different in scope to the original claims. Example 1

[0094]

[0130] Example 1 is a device for use intravenously, comprising a first member and a second member, each of the first member and the second member including a flexible joint dividing the member into a first portion having a first segment end and a second segment having a second segment end, the first segment end and the second segment end being distal to the flexible joint, the first end being connected to the first segment of the first member and the second end being connected to the first segment of the second member, the first end being connected to the first segment of the first member distal to the first end. The flexible joint includes a cross member, the cross member being connected to each first segment closer to a first segment end of each first segment than the flexible joint of each member, a first joint member connected to a second segment of the first member closer to the flexible joint of the first member than the second segment end of the first member, and a second joint member connected to the second segment of the second member closer to the flexible joint of the second member than the second segment end of the second member, the cross member, the first joint member and the second joint member each being deformable along a longitudinal axis.

[0095]

[0131] Example 2 includes the subject matter of Example 1 or any other example herein, wherein the first joint member includes a third end distal to the flexible joint of the first member and the second joint member includes a second end distal to the flexible joint of the fourth member, each first segment end configured to flexibly couple to a second segment end of a first adjacent device and the third end configured to join to a second end of a fourth adjacent device.

[0096]

[0132] Example 3 includes the subject matter of example 1 or example 2, or any other example herein, where the device is made from a shape memory material that can be plastically deformed below a predetermined temperature and returns to an undeformed shape above the predetermined temperature.

[0097]

[0133] Example 4 includes the subject matter of Example 3 or other embodiments in which the device is fabricated from a nickel-titanium alloy.

[0098]

[0134] Example 5 includes the subject matter of any of Examples 1-4, or any other example herein, wherein the first and second joining members are curved and attached at an acute angle to the first and second members, respectively.

[0099]

[0135] Example 6 includes a stent having a plurality of cells, a cross member, a first junction member, and a second junction member, each of the plurality of cells comprising a first member and a second member, each of the first member and the second member comprising a flexible joint dividing the member into a first portion having a first segment end and a second portion having a second segment end, the first segment end and the second segment end being distal to the flexible joint, the cross member having a first end connected to the first segment of the first member proximate the first segment end of the first member and a second portion distal to the first end and proximate the first segment end of the second member. a first segment of a second member adjacent to the first segment and a second end connected to each first segment distal from the flexible joint of each member, the first joint member being connected to the second segment of the first member proximate the flexible joint of the first member and distal from the second segment end of the first member, and the second joint member being connected to the second segment of the second member proximate the flexible joint of the second member and distal from the second segment end of the second member, and the plurality of cells are interconnected with each other via one or more of the first segment end, the second segment end, the first joint member, and / or the second joint member of each cell.

[0100]

[0136] Example 7 includes the subject matter of Example 6, or any other example herein, in which a plurality of cells are interconnected to form a tubular structure.

[0101]

[0137] Example 8 includes the subject matter of Example 7 or any other example herein, wherein the plurality of cells comprises a first set of cells, a second set of cells, and a third set of cells, each of the first, second, and third sets of cells comprising a tubular structure, the first set of cells being axially attached to first ends of the second set of cells, and the second set of cells being axially attached to second ends of the second set of cells.

[0102]

[0138] Example 9 includes the subject matter of example 7 or example 8, or any other example herein, wherein the stent has a first end and a second end, one of the ends including a plurality of protrusions.

[0103]

[0139] Example 10 includes the subject matter of any of Examples 7-9, or any other example herein, wherein the stent includes a plurality of protrusions axially disposed along the stent.

[0104]

[0140] Example 11 includes the subject matter of any of Examples 7-10, or any other example herein, wherein each of the plurality of cells is made from a shape memory material that is capable of plastic deformation below a predetermined temperature and returns to an undeformed shape above the predetermined temperature.

[0105]

[0141] Example 12 includes the subject matter of Example 11 or other embodiments in which the stent is made from a nickel-titanium alloy.

[0106]

[0142] Example 13 includes the subject matter of any of Examples 6-12, or any other example herein, wherein each first joint member and second joint member of each cell is connected to its respective first member and second member with an acute bend.

[0107]

[0143] Example 14 is a method of controlling stenosis of a body passage, comprising inserting a tubular shaped stent into a portion of a passage that is partially or totally occluded, and radially expanding the stent to a predetermined diameter to relieve the occlusion of the passage, the stent being configured to expand axially as the diameter of the stent increases, the stent being comprised of a plurality of cells, cross members, a first junction member, and a second junction member, each of the plurality of cells comprising a first member and a second member, each of the first member and the second member comprising a flexible junction that divides the member into a first portion having a first segment end and a second portion having a second segment end. , the first segment end and the second segment end are distal from the flexible joint, the cross member has a first end connected to the first segment of the first member proximate the first segment end of the first member and a second end connected to the first segment of the second member distal from the first end and proximate the first segment end of the second member, and is connected to each first segment distal from the flexible joint of each member, the first joint member is connected to the second segment of the first member proximate the flexible joint of the first member and distal from the second segment end of the first member, and the second joint member is connected to the second segment of the second member proximate the flexible joint of the second member and distal from the second segment end of the second member.

[0108]

[0144] Example 15 includes the subject matter of Example 14 or any other example herein, wherein the duct is one or a portion of a bile duct, a genitourinary tract, a gastrointestinal tract, a tracheobronchial structure, a sinus, a salivary gland, a salivary gland duct, a lymphatic duct, a surgical enterostomy, a surgical arteriovenous fistula or graft, a surgical anastomosis of at least two body structures, or an artery.

[0109]

[0145] Example 16 includes the subject matter of either Example 14 or 15, or any other example herein, further including axially expanding or compressing the stent to a predetermined length that prevents occlusion of a portion of the vein adjacent to the partially or totally occluded vein segment while maintaining the predetermined diameter.

[0110]

[0146] Example 17 includes the subject matter of any of Examples 14-16, or any other example herein, further including axially expanding or compressing a first portion of the stent to a different axial length than a second portion of the stent to place the stent in an axially curved configuration.

[0111]

[0147] Example 18 includes the subject matter of any of Examples 14-17, or any other example herein, further including radially compressing the stent prior to inserting the stent.

[0112]

[0148] Example 19 includes the subject matter of any of Examples 14-18, or any other example herein, where the stent is configured to plastically deform below a predetermined temperature and return to an undeformed shape above the predetermined temperature, and the stent is radially compressed prior to insertion below the predetermined temperature.

[0113]

[0149] Example 20 includes the subject matter of Example 19, or any other example herein, wherein the predetermined temperature is less than 37°C.

Claims

1. In a cell (500) for intravenous use, a first strut (602) including a curved portion, said first strut (602) comprising a first flexible joint (606) at a curved portion of said first strut (602), said first flexible joint (606) dividing said first strut (602) into a first segment (602a) having a first segment end (626) and a second segment (602b) having a second segment end (630), said first segment end (626) of said first strut (602) being distal from said first flexible joint (606) and said second segment end (630) being distal from said first flexible joint (606); a second strut (604) including a curved portion, the second strut (604) comprising a second flexible joint (608) at the curved portion of the second strut (604), the second flexible joint (608) dividing the second strut (604) into a first segment (604a) having a first segment end (628) and a second segment (604b) having a second segment end (632), the first segment end (628) of the second strut (604) being distal from the second flexible joint (608), and the second segment end (632) of the second strut (604) being distal from the second flexible joint (608); a cross member (610) having a first end connected to the first segment (602 a) of the first strut (602) and a second end connected to the first segment (604 a) of the second strut (604), the first end being closer to a first segment end (626) of the first segment (602 a) of the first strut (602) than a first flexible joint (606) of the first strut (602) and the second end being closer to a first segment end (628) of the first segment (604 a) of the second strut (604) than a second flexible joint (608) of the second strut (604); a first joint member (614) connected to the second segment (602b) of the first strut (602) and closer to the first flexible joint (606) of the first strut (602) than the second segment end (630) of the first strut (602); a second joint member (620) connected to the second segment (604b) of the second strut (604) and closer to the second flexible joint (608) of the second strut (604) than the second segment end (632) of the second strut (604); Equipped with The cross member (610), the first joint member (614), and the second joint member (620) are each deformable, and the cell (500) is configured such that expansion of the device in the radial direction results in expansion of the device in the longitudinal direction.

2. the first joint member includes a third end; the second joint member includes a fourth end; each first segment end configured to flexibly join a second segment end of a first adjacent cell; The cell of claim 1 , wherein the third end is configured to mate with a fourth end of a second adjacent cell.

3. 3. The cell of claim 1 or 2, wherein the cell is made from a shape memory material that can be plastically deformed below a predetermined temperature and returns to its undeformed shape above the predetermined temperature.

4. The cell of claim 3 , wherein the cell is made from a nickel-titanium alloy.

5. A cell as described in any one of claims 1 to 4, wherein the angle formed between the first joining member (614) and the second segment (602a) of the first support (602) and the angle formed between the second joining member (620) and the second segment (604b) of the second support (604) are both acute angles.

6. 2. A stent comprising the cells of claim 1, A stent, wherein the cells are interconnected with each other via one or more of each cell's first segment end, second segment end, first joint member, and / or second joint member, and the stent is configured such that expansion of the stent in a radial direction is expansion of the stent in a longitudinal direction.

7. The stent of claim 6 , wherein the plurality of cells are interconnected to form a tubular structure.

8. the plurality of cells comprises a first cell set, a second cell set, and a third cell set; 8. The stent of claim 7, wherein each of the first cell set, the second cell set, and the third cell set comprises a tubular structure, the first cell set being axially attached to a first end of the second cell set, and the third cell set being axially attached to a second end of the second cell set.

9. 9. The stent of claim 7 or 8, wherein the stent has a first end and a second end, one of the ends comprising a plurality of barbs.

10. The stent of any one of claims 7 to 9, wherein the stent comprises a plurality of projections arranged axially along the stent.

11. The stent of any one of claims 7 to 10, wherein each of the plurality of cells is made from a shape memory material that can be plastically deformed at a temperature below a predetermined temperature and returns to an undeformed shape at a temperature above the predetermined temperature.

12. The stent of claim 11 , wherein the stent is made from a nickel-titanium alloy.

13. A stent as described in any one of claims 6 to 12, wherein the angle formed between the first joint member (614) of each cell (500) and the second segment (602b) of the first strut (602) and the angle formed between the second joint member (620) of each cell (500) and the second segment (604b) of the second strut (604) are both acute angles.

Citation Information

Patent Citations

  • intravascular stent device

    JP2005506094A

  • expandable tubular liner

    JP2005534396A

  • intravascular stent

    JP2006520239A

  • A new type of slide-lock bioabsorbable stent and its use

    JP2014500048A

  • Auxetic stents

    US20110029063A1